nodes	percent_of_prediction	percent_of_DWPC	metapath
Terlipressin—Fluid overload—Carboplatin—bone cancer	0.117	0.145	CcSEcCtD
Terlipressin—Skin necrosis—Cisplatin—bone cancer	0.061	0.0756	CcSEcCtD
Terlipressin—Fluid overload—Cisplatin—bone cancer	0.0343	0.0425	CcSEcCtD
Terlipressin—Skin necrosis—Methotrexate—bone cancer	0.0335	0.0415	CcSEcCtD
Terlipressin—Skin necrosis—Epirubicin—bone cancer	0.0313	0.0388	CcSEcCtD
Terlipressin—Skin necrosis—Doxorubicin—bone cancer	0.029	0.0359	CcSEcCtD
Terlipressin—Skin exfoliation—Cisplatin—bone cancer	0.0204	0.0252	CcSEcCtD
Terlipressin—Cyanosis—Methotrexate—bone cancer	0.0165	0.0205	CcSEcCtD
Terlipressin—Hyponatraemia—Cisplatin—bone cancer	0.0155	0.0193	CcSEcCtD
Terlipressin—Ventricular extrasystoles—Epirubicin—bone cancer	0.0121	0.015	CcSEcCtD
Terlipressin—Respiratory failure—Methotrexate—bone cancer	0.0119	0.0148	CcSEcCtD
Terlipressin—Acute coronary syndrome—Cisplatin—bone cancer	0.0118	0.0146	CcSEcCtD
Terlipressin—Myocardial infarction—Cisplatin—bone cancer	0.0117	0.0145	CcSEcCtD
Terlipressin—Ventricular extrasystoles—Doxorubicin—bone cancer	0.0112	0.0139	CcSEcCtD
Terlipressin—Skin exfoliation—Methotrexate—bone cancer	0.0112	0.0138	CcSEcCtD
Terlipressin—Bradycardia—Cisplatin—bone cancer	0.0109	0.0135	CcSEcCtD
Terlipressin—Skin exfoliation—Epirubicin—bone cancer	0.0105	0.013	CcSEcCtD
Terlipressin—Pulmonary oedema—Methotrexate—bone cancer	0.0104	0.0129	CcSEcCtD
Terlipressin—AVPR1B—G alpha (q) signalling events—GRM1—bone cancer	0.0101	0.0523	CbGpPWpGaD
Terlipressin—Cardiac disorder—Cisplatin—bone cancer	0.00994	0.0123	CcSEcCtD
Terlipressin—Pulmonary oedema—Epirubicin—bone cancer	0.00975	0.0121	CcSEcCtD
Terlipressin—Skin exfoliation—Doxorubicin—bone cancer	0.00968	0.012	CcSEcCtD
Terlipressin—Malnutrition—Cisplatin—bone cancer	0.00932	0.0116	CcSEcCtD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00903	0.0468	CbGpPWpGaD
Terlipressin—Pulmonary oedema—Doxorubicin—bone cancer	0.00902	0.0112	CcSEcCtD
Terlipressin—Hot flush—Epirubicin—bone cancer	0.0085	0.0105	CcSEcCtD
Terlipressin—Menopausal symptoms—Epirubicin—bone cancer	0.00843	0.0104	CcSEcCtD
Terlipressin—Cardiac failure—Epirubicin—bone cancer	0.00815	0.0101	CcSEcCtD
Terlipressin—Hyponatraemia—Epirubicin—bone cancer	0.00798	0.00989	CcSEcCtD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00788	0.00977	CcSEcCtD
Terlipressin—Hot flush—Doxorubicin—bone cancer	0.00786	0.00975	CcSEcCtD
Terlipressin—Menopausal symptoms—Doxorubicin—bone cancer	0.0078	0.00966	CcSEcCtD
Terlipressin—Cardiac failure—Doxorubicin—bone cancer	0.00754	0.00934	CcSEcCtD
Terlipressin—Nervous system disorder—Cisplatin—bone cancer	0.00746	0.00925	CcSEcCtD
Terlipressin—Tachycardia—Cisplatin—bone cancer	0.00743	0.0092	CcSEcCtD
Terlipressin—Skin disorder—Cisplatin—bone cancer	0.00739	0.00916	CcSEcCtD
Terlipressin—Hyponatraemia—Doxorubicin—bone cancer	0.00739	0.00915	CcSEcCtD
Terlipressin—AVPR1A—G alpha (q) signalling events—GRM1—bone cancer	0.00699	0.0362	CbGpPWpGaD
Terlipressin—Dyspnoea—Cisplatin—bone cancer	0.00678	0.00841	CcSEcCtD
Terlipressin—Gastrointestinal disorder—Cisplatin—bone cancer	0.00657	0.00814	CcSEcCtD
Terlipressin—AVPR1B—G alpha (q) signalling events—GNA11—bone cancer	0.0065	0.0337	CbGpPWpGaD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00626	0.0324	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR ligand binding—GRM4—bone cancer	0.00587	0.0304	CbGpPWpGaD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00582	0.0301	CbGpPWpGaD
Terlipressin—Bradycardia—Epirubicin—bone cancer	0.0056	0.00694	CcSEcCtD
Terlipressin—Cardiac disorder—Methotrexate—bone cancer	0.00545	0.00676	CcSEcCtD
Terlipressin—Angiopathy—Methotrexate—bone cancer	0.00533	0.00661	CcSEcCtD
Terlipressin—Diarrhoea—Cisplatin—bone cancer	0.00521	0.00645	CcSEcCtD
Terlipressin—Bradycardia—Doxorubicin—bone cancer	0.00518	0.00642	CcSEcCtD
Terlipressin—Malnutrition—Methotrexate—bone cancer	0.00512	0.00634	CcSEcCtD
Terlipressin—Cardiac disorder—Epirubicin—bone cancer	0.0051	0.00633	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—GRM1—bone cancer	0.00509	0.0264	CbGpPWpGaD
Terlipressin—Angiopathy—Epirubicin—bone cancer	0.00499	0.00618	CcSEcCtD
Terlipressin—Vomiting—Cisplatin—bone cancer	0.00484	0.006	CcSEcCtD
Terlipressin—Malnutrition—Epirubicin—bone cancer	0.00479	0.00593	CcSEcCtD
Terlipressin—Cardiac disorder—Doxorubicin—bone cancer	0.00472	0.00585	CcSEcCtD
Terlipressin—Angiopathy—Doxorubicin—bone cancer	0.00462	0.00572	CcSEcCtD
Terlipressin—Nausea—Cisplatin—bone cancer	0.00452	0.0056	CcSEcCtD
Terlipressin—AVPR1A—G alpha (q) signalling events—GNA11—bone cancer	0.00451	0.0234	CbGpPWpGaD
Terlipressin—Malnutrition—Doxorubicin—bone cancer	0.00443	0.00549	CcSEcCtD
Terlipressin—Chest pain—Methotrexate—bone cancer	0.00436	0.0054	CcSEcCtD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00433	0.00536	CcSEcCtD
Terlipressin—Hypertension—Epirubicin—bone cancer	0.00413	0.00512	CcSEcCtD
Terlipressin—Nervous system disorder—Methotrexate—bone cancer	0.0041	0.00507	CcSEcCtD
Terlipressin—Chest pain—Epirubicin—bone cancer	0.00408	0.00505	CcSEcCtD
Terlipressin—AVPR1A—GPCR ligand binding—GRM4—bone cancer	0.00407	0.0211	CbGpPWpGaD
Terlipressin—Skin disorder—Methotrexate—bone cancer	0.00406	0.00503	CcSEcCtD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00405	0.00502	CcSEcCtD
Terlipressin—AVPR2—GPCR ligand binding—GRM4—bone cancer	0.00404	0.0209	CbGpPWpGaD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00403	0.0209	CbGpPWpGaD
Terlipressin—Nervous system disorder—Epirubicin—bone cancer	0.00383	0.00475	CcSEcCtD
Terlipressin—Hypertension—Doxorubicin—bone cancer	0.00383	0.00474	CcSEcCtD
Terlipressin—Tachycardia—Epirubicin—bone cancer	0.00381	0.00473	CcSEcCtD
Terlipressin—Skin disorder—Epirubicin—bone cancer	0.0038	0.0047	CcSEcCtD
Terlipressin—Chest pain—Doxorubicin—bone cancer	0.00377	0.00467	CcSEcCtD
Terlipressin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00375	0.00464	CcSEcCtD
Terlipressin—Dyspnoea—Methotrexate—bone cancer	0.00372	0.00461	CcSEcCtD
Terlipressin—Gastrointestinal disorder—Methotrexate—bone cancer	0.00361	0.00447	CcSEcCtD
Terlipressin—AVPR1B—GPCR ligand binding—SMO—bone cancer	0.00359	0.0186	CbGpPWpGaD
Terlipressin—Nervous system disorder—Doxorubicin—bone cancer	0.00355	0.00439	CcSEcCtD
Terlipressin—Tachycardia—Doxorubicin—bone cancer	0.00353	0.00437	CcSEcCtD
Terlipressin—AVPR1A—GPCR ligand binding—GRM1—bone cancer	0.00353	0.0183	CbGpPWpGaD
Terlipressin—Skin disorder—Doxorubicin—bone cancer	0.00351	0.00435	CcSEcCtD
Terlipressin—AVPR2—GPCR ligand binding—GRM1—bone cancer	0.0035	0.0181	CbGpPWpGaD
Terlipressin—Dyspnoea—Epirubicin—bone cancer	0.00348	0.00432	CcSEcCtD
Terlipressin—Gastrointestinal disorder—Epirubicin—bone cancer	0.00337	0.00418	CcSEcCtD
Terlipressin—AVPR2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00333	0.0172	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—RGS1—bone cancer	0.00332	0.0172	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—GRM4—bone cancer	0.00332	0.0172	CbGpPWpGaD
Terlipressin—Abdominal pain—Methotrexate—bone cancer	0.0033	0.00409	CcSEcCtD
Terlipressin—Dyspnoea—Doxorubicin—bone cancer	0.00322	0.00399	CcSEcCtD
Terlipressin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00312	0.00387	CcSEcCtD
Terlipressin—Abdominal pain—Epirubicin—bone cancer	0.00309	0.00383	CcSEcCtD
Terlipressin—AVPR1B—Signaling by GPCR—GRM4—bone cancer	0.00301	0.0156	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—RGS1—bone cancer	0.00301	0.0156	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—GRM1—bone cancer	0.00288	0.0149	CbGpPWpGaD
Terlipressin—AVPR2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00287	0.0149	CbGpPWpGaD
Terlipressin—Abdominal pain—Doxorubicin—bone cancer	0.00286	0.00354	CcSEcCtD
Terlipressin—Diarrhoea—Methotrexate—bone cancer	0.00286	0.00354	CcSEcCtD
Terlipressin—Diarrhoea—Epirubicin—bone cancer	0.00267	0.00331	CcSEcCtD
Terlipressin—Vomiting—Methotrexate—bone cancer	0.00266	0.00329	CcSEcCtD
Terlipressin—Headache—Methotrexate—bone cancer	0.00262	0.00324	CcSEcCtD
Terlipressin—AVPR1B—Signaling by GPCR—GRM1—bone cancer	0.00261	0.0135	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR ligand binding—SMO—bone cancer	0.00249	0.0129	CbGpPWpGaD
Terlipressin—Vomiting—Epirubicin—bone cancer	0.00248	0.00308	CcSEcCtD
Terlipressin—Nausea—Methotrexate—bone cancer	0.00248	0.00307	CcSEcCtD
Terlipressin—Diarrhoea—Doxorubicin—bone cancer	0.00247	0.00307	CcSEcCtD
Terlipressin—AVPR2—GPCR ligand binding—SMO—bone cancer	0.00247	0.0128	CbGpPWpGaD
Terlipressin—Headache—Epirubicin—bone cancer	0.00245	0.00303	CcSEcCtD
Terlipressin—Nausea—Epirubicin—bone cancer	0.00232	0.00288	CcSEcCtD
Terlipressin—AVPR1A—GPCR downstream signaling—RGS1—bone cancer	0.0023	0.0119	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—GRM4—bone cancer	0.0023	0.0119	CbGpPWpGaD
Terlipressin—Vomiting—Doxorubicin—bone cancer	0.0023	0.00285	CcSEcCtD
Terlipressin—AVPR2—GPCR downstream signaling—GRM4—bone cancer	0.00228	0.0118	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—RGS1—bone cancer	0.00228	0.0118	CbGpPWpGaD
Terlipressin—Headache—Doxorubicin—bone cancer	0.00227	0.00281	CcSEcCtD
Terlipressin—Nausea—Doxorubicin—bone cancer	0.00215	0.00266	CcSEcCtD
Terlipressin—AVPR1A—Signaling by GPCR—RGS1—bone cancer	0.00209	0.0108	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—GRM4—bone cancer	0.00209	0.0108	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—GRM4—bone cancer	0.00207	0.0107	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—RGS1—bone cancer	0.00207	0.0107	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—GRM1—bone cancer	0.00199	0.0103	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—GRM1—bone cancer	0.00198	0.0103	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—GNA11—bone cancer	0.00185	0.0096	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—SMO—bone cancer	0.00184	0.00953	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—GRM1—bone cancer	0.00181	0.00938	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—GRM1—bone cancer	0.0018	0.00931	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—RGS1—bone cancer	0.00178	0.00922	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—GRM4—bone cancer	0.00178	0.00922	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—GNA11—bone cancer	0.00168	0.00872	CbGpPWpGaD
Terlipressin—AVPR1B—GPCR downstream signaling—IL3—bone cancer	0.00168	0.00871	CbGpPWpGaD
Terlipressin—AVPR1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.00166	0.00858	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—GRM1—bone cancer	0.00154	0.00799	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—IL3—bone cancer	0.00153	0.00791	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—GNA11—bone cancer	0.00128	0.00666	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—SMO—bone cancer	0.00128	0.00661	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—GNA11—bone cancer	0.00128	0.00661	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—SMO—bone cancer	0.00127	0.00656	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—GRM4—bone cancer	0.00123	0.00639	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—RGS1—bone cancer	0.00123	0.00639	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—GRM4—bone cancer	0.00122	0.00635	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—RGS1—bone cancer	0.00122	0.00635	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—GNA11—bone cancer	0.00117	0.00604	CbGpPWpGaD
Terlipressin—AVPR1A—GPCR downstream signaling—IL3—bone cancer	0.00116	0.00603	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—GNA11—bone cancer	0.00116	0.006	CbGpPWpGaD
Terlipressin—AVPR2—GPCR downstream signaling—IL3—bone cancer	0.00116	0.00599	CbGpPWpGaD
Terlipressin—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.00115	0.00595	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—SMO—bone cancer	0.00109	0.00563	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—GRM1—bone cancer	0.00107	0.00554	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—GRM1—bone cancer	0.00106	0.0055	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—IL3—bone cancer	0.00106	0.00548	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—IL3—bone cancer	0.00105	0.00544	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—GNA11—bone cancer	0.000994	0.00515	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—ATF1—bone cancer	0.000924	0.00479	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—IL3—bone cancer	0.000901	0.00467	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—TGFBR2—bone cancer	0.000771	0.00399	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—SMO—bone cancer	0.000753	0.0039	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—SMO—bone cancer	0.000748	0.00388	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—IGF1R—bone cancer	0.000725	0.00376	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—GNA11—bone cancer	0.000689	0.00357	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—GNA11—bone cancer	0.000684	0.00355	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—ATF1—bone cancer	0.000641	0.00332	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—ATF1—bone cancer	0.000636	0.0033	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—IL3—bone cancer	0.000625	0.00324	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—IL3—bone cancer	0.00062	0.00321	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—TGFBR2—bone cancer	0.000534	0.00277	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TGFBR2—bone cancer	0.000531	0.00275	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—KIT—bone cancer	0.000526	0.00273	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—IGF1R—bone cancer	0.000503	0.0026	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—IGF1R—bone cancer	0.000499	0.00259	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—BRAF—bone cancer	0.000494	0.00256	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling by GPCR—EGFR—bone cancer	0.000479	0.00248	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—MDM2—bone cancer	0.000414	0.00215	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—KIT—bone cancer	0.000365	0.00189	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—KIT—bone cancer	0.000362	0.00188	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—JUN—bone cancer	0.00036	0.00187	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—MMP9—bone cancer	0.00035	0.00182	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—BRAF—bone cancer	0.000343	0.00178	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—BRAF—bone cancer	0.00034	0.00176	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling by GPCR—EGFR—bone cancer	0.000332	0.00172	CbGpPWpGaD
Terlipressin—AVPR2—Signaling by GPCR—EGFR—bone cancer	0.00033	0.00171	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—MDM2—bone cancer	0.000287	0.00149	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—MDM2—bone cancer	0.000285	0.00148	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—EGFR—bone cancer	0.000283	0.00147	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—JUN—bone cancer	0.00025	0.00129	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—JUN—bone cancer	0.000248	0.00128	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—MMP9—bone cancer	0.000243	0.00126	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—MMP9—bone cancer	0.000241	0.00125	CbGpPWpGaD
Terlipressin—AVPR1B—Signaling Pathways—TP53—bone cancer	0.000238	0.00123	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—EGFR—bone cancer	0.000196	0.00102	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—EGFR—bone cancer	0.000195	0.00101	CbGpPWpGaD
Terlipressin—AVPR1A—Signaling Pathways—TP53—bone cancer	0.000165	0.000854	CbGpPWpGaD
Terlipressin—AVPR2—Signaling Pathways—TP53—bone cancer	0.000164	0.000848	CbGpPWpGaD
